Chromosomal Aberration Scoring for HRD Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment methods lack effective molecular diagnostic tools to characterize patient-specific cancer characteristics for personalized treatment plans, particularly in assessing homologous recombination deficiency (HRD) in cancer cells.
Innovation Solution
A method involving the detection and analysis of chromosomal aberrations (CA Regions) such as LOH, TAI, and LST in cancer cells to determine HRD, using a combined analysis of these regions to assess HRD through determining their number, size, and character, and calculating CA Region Scores to predict treatment responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If molecular diagnostic tools are used to characterize patient-specific cancer characteristics, then treatment personalization is improved, but device complexity and measurement precision requirements increase
Solution Approach 1:
The patent segments the complex task of HRD assessment into distinct chromosomal aberration types (LOH regions, TAI regions, LST regions), each detected and analyzed separately before being integrated into a comprehensive HRD score. This segmentation simplifies the overall diagnostic process by breaking down the complex molecular characterization into manageable, standardized components that can be detected using established genomic technologies.
2Measurement precision
If comprehensive chromosomal aberration analysis is performed to assess HRD, then measurement precision is improved, but difficulty of detecting and measuring increases
Solution Approach 1:
The patent employs a universal scoring system (CA Region Score) that integrates multiple types of chromosomal aberrations (LOH, TAI, LST) into a single comprehensive HRD assessment metric. This multi-functional approach allows the same analytical framework to evaluate different aberration types uniformly, improving measurement precision while simplifying the interpretation complexity through standardized scoring criteria.
3Reliability
If multiple types of chromosomal aberration regions are analyzed, then reliability of HRD assessment is improved, but device complexity and analysis time increase
Solution Approach 1:
The patent merges multiple types of chromosomal aberration analyses (LOH regions, TAI regions, LST regions) into a unified HRD assessment framework. By combining these different aberration types into a single integrated scoring system, the patent improves reliability through comprehensive evaluation while managing complexity through standardized integration protocols that can be implemented using existing genomic analysis platforms.
Data Source
AI summary
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.